Cardiology Update 2025: Two Volume Set

VOLUME 1
Preventive Cardiology (Section - 1)
1            Improving community level cardiac health awareness through school based education programs in India
2            Air Pollution & CVD in India: Current Perspective
3            Can  we cancel out the excess Cardiovascular Risk Caused by Chronic Kidney Disease
4            Smoking Cessation: Never too Early, Never too Late
 
Hypertension (Section - 2)
5            Implications of Systolic Blood Pressure Time in Target Range
6            Artificial Intelligence - A Potential Tool in the Diagnosis and Management of Hypertension
7            Clinical Management of Primary Aldosteronism
8            Implications of Myocardial Interstitial Fibrosis in Hypertensive Heart Disease
9            Renovascular Hypertension: Kidney Intrinsic Mechanisms as Novel Targets
10          The Complexity of Resistant and Refractory Hypertension
 
Cardiometabolic (Section - 3)
11          Slowing cardiovascular aging by promoting cardiometabolic health
12          Obesity and Cardiovascular Disease
13          Myocardial Abnormalities Across the AHA - ACC Heart Failure Spectrum in Diabetic Patients
 
 Dyslipidemia Management (Section - 4)
14          Implications of lipid lowering therapy for premature CAD
15          The challenges in reducing Non-HDL- cholesterol.
16          Particle Number and Characteristics of Lipoprotein(a), LDL, and apoB: Contributions to ASCVD
17          Impact of Childhood Non-HDL Cholesterol and LDL Cholesterol on Adult Atherosclerotic Cardiovascular Events
 
Heart Failure (Section - 5)
18          WHF - How to Predict and Treat Early
19          Pulmonary hypertension in heart failure
20          Progression from Pre-Heart Failure, Heart Stress to Subclinical Heart Failure
21          Human immunology of heart failure
22          Identification of iron deficiency states and effective iron repletion strategies in patients with chronic heart failure
23          Risk Scores in the Management of Heart Failure
24          Issues in Reversing Advanced Heart Failure
25          Early initiation of GDMT in HF
26          Mixed Cardiogenic-Vasodilatory Shock
27          Chronic right-sided heart failure and tricuspid regurgitation
28          Neuromodulation interventions in the management of heart failure
29          Congestion and Diuretic Resistance in WHF
30          Role of Imaging in Heart Failure Risk Stratification
31          Can Left Ventricular Wall Strain predict Heart Failure?
32          Medical therapy of cardiogenic shock
33          From Pre-shock to Classic Cardiogenic Shock
34          Triaging of Patients of ADHF
35          Gut hypothesis of heart failure: role of gut microbiota-derived metabolites
36          Strategies for Diuretic Intensification in Acute Heart Failure
37          Approaches in Heart Failure With Mildly Reduced and Preserved Ejection Fraction
38          Characteristics and Outcomes of Patients with Valvular Cardiogenic Shock
39          Hemodynamic Assessment by Right Heart Catheterization in Management of Heart Failure
 
Cardiomyopathy (Section - 6)
40          Risk Predictors of Sudden Cardiac Death in Hypertrophic Cardiomyopathy
41          Monogenic to Polygenic Clinical Genetic Testing in Hypertrophic Cardiomyopathy
42          Dual Ischemic and Nonischemic Cardiomyopathy
43          Predicting Risk of Sudden Cardiac Death in Hypertrophic Cardiomyopathy by Myocardial Strain
44          Role of Clonal Haematopoiesis in the Pathogenesis of Dilated Cardiomyopathy
45          Dilated Cardiomyopathy in Systemic Immune-Mediated Diseases
46          Arrhythmia induced Cardiomyopathy
47          Alcoholic Cardiomyopathy
 
Congenital Heart Disease (Section - 7)
48          The Expanding Future of Sinus Venosus ASD Closure
49          Congenital Heart Disease Across the Lifespan: Clinical Risk Assessment and Prediction
50          Early Intervention for Tetralogy of Fallot
51          Novel Imaging Techniques for Congenital Heart Disease
52          Chronic Heart Failure in Children and Adolescents With Congenital Heart Disease
53          Recent advances in the management of Adult Congenital Heart Disease-Related Heart Failure
54          Congenital Heart Disease in India : The Evolving Landscape
55          Echocardiography for Childhood Left Ventricular Noncompaction
56          Adults with congenital heart disease_ what every cardiologist should know about their care
57          Repaired Tetralogy of Fallot: Quest for a Lifelong Pulmonary Valve
 
Valvular Heart Disease (Section - 8)
58          Multiparametric Approach to Asymptomatic Aortic Stenosis
59          Secondary Mitral Regurgitation Phenotypes
60          Mitral Annular Disjunction in Mitral Valve Prolapse
61          An Update on High-Gradient “Moderate” Aortic Stenosis
62          Comprehensive Risk Phenotyping in Aortic Stenosis
63          When to Treat Young and Low-Risk Patients with Aortic Stenosis
64          Rheumatic Fever and Rheumatic Heart Disease Continuum: Recent Advances
65          Comprehensive Approach to Aortic Valve Pathophysiology by Fibro-Calcific Imaging
66          ESC 2025 Guidelines on Valvular Heart Disease
67          RHD in India: Current Perspective
 
Cardio-Obstetrics (Section - 9)
68          Cardiac Interventions in Pregnancy
69          Antepartum CV risk assessment and management of high-risk cardiac delivery.
70          Understanding and Managing Heart Failure during Pregnancy – What’s New in Peripartum Cardiomyopathy
71          Hypertensive Disorder of Pregnancy and Long-Term Cardiovascular Outcome
72          Understanding and Managing Anticoagulation during Pregnancy in Women with Heart Valves
 
Coronary Artery Disease (Section - 10)
73          Sarcopenia in Coronary Microvascular Dysfunction
74          Spontaneous Coronary Artery Dissection
75          Influence of Platelet biology and function on plaque erosion vs rupture
76          Coronary Artery Aneurysms
77          Atherosclerosis, Aortic Dissection, and Peripheral Artery Disease: New Therapeutic Targets
             
 
Cardiac  Arrhythmia (Section - 11)
78          Stable VT in Ischemic Cardiomyopathy and LVEF < 35%: Ablation vs ICD
79          Long-term CV Outcome of Atrial Fibrillation
80          Effect of Left Atrial Dyssynchrony on Long-term Clinical Outcome during Cardiac Resynchronization Therapy
81          Real World Management of Cardiac Implantable Electronic Device Infections
82          Past, Present and Future of Leadless Pacing
83          Atrial fibrillation in Hf. Role of catheter ablation
84          Ablation of Ventricular Tachycardia in Emergency Situations
85          Prevention of Sudden Cardiac Death Beyond Automated External Defibrillators and Implantable Cardioverter Defibrillators
86          Current Perspective of Pulsed Field Ablation
87          Para-Hisian Ventricular Arrhythmias
 
Imaging (Section - 12)
88          Risk Stratification with CCTA derived Fractional Flow Reserve and Fractional Flow Reserve Gradient
89          Multi-modality Imaging in Multiple Valvular Heart Diseases
90          Role of LA Indices in the Management of Chronic Severe Aortic Regurgitation
91          Application of Emerging Hybrid Intracoronary Imaging Technologies in Clinical Practice and Research
92          Current Concepts and Clinical Implications of Coronary Artery Calcification
93          Cardiac CT: Emerging Role in Microvascular Dysfunction
94          Role of Cardiac Imaging for Optimizing Medical Therapy
 
 
VOLUME 2
STEMI (Section - 13)
95          P2Y12 Inhibitor Pretreatment in STEMI
96          STEMI Revascularization in India: Lessons Learnt from Punjab
97          Cardiac Magnetic Resonance Evaluation of LV Remodeling after Myocardial Infarction
98          Recurrent Thrombosis after Myocardial Infarction
99          STEMI Revascularization in India: Lessons Learnt from Tamil Nadu – 5 years experience
100        Thrombolysis in STEMI in Primary PTCA Era – Current Relevance in India
101        STEMI Revascularization in India: Lessons Learnt from Goa
102        Role of Novel Risk Factors in STEMI Among Young Women.
103        Transition from ST-Segment Elevation MI to Occlusion MI .
104        STEMI Revascularization in India: Role of Thrombolysis in Ambulance
105        Addressing delays in reperfusion therapy - Developing Chest Pain Clinics - A new initiative from STEMI India
106        Advanced Cardiac Patches in the Treatment of Myocardial Infarction
 
Coronary Intervention (Section - 14)
107        Thrombus Aspiration in Primary Angioplasty
108        Evaluation of Microvascular Dysfunction during Diagnostic Coronary Angiography
109        Prevention of  progression of obesity and Cardiometabolic Disease: Intervention in School-Aged Children
110        Perforations in Complex PCI
111        Coronary Physiology by different Approaches for Guiding PCI
112        Left Main Bifurcation ISR - What to do?
113        Management of Drug - Eluting Stent In-Stent Restenosis
114        Bailout Strategies in CTO PCI
115        Metalless PCI
116        Percutaneous coronary intervention in high risk renal disorders :strategies for renal protection
117        Effect of Anatomical and Viability - Guided Completeness of Revascularization on Clinical Outcomes in Ischemic Cardiomyopathy
118        Dual Antiplatelet Therapy in CKD: Duration and Bleeding Risk in Post PCI Patients
119        Technological Progress in Treating Calcified Lesion
120        PCI in Multivessel Coronary Artery Disease - Outcome According to the Coronary Lesion Complexity
 
Structural Intervention  (Section - 15)
121        Transcatheter Aortic Valve Replacement in Heart Failure
122        Antithrombotic Selection Post - Left Atrial Appendage Occlusion
123        Predictors of Outcome of Re-interventions after TAVR
124        Implications of Left Bundle Branch Block in Aortic Stenosis beyond Pacemaker Implantation
125        Imaging of Transcatheter Valve Failure: An Update
126        Transcatheter Treatment of Pure Aortic Regurgitation
127        Transcatheter Mitral Therapy: Changing Context and Goals
128        Unveiling Right Ventricle Remodeling Following Tricuspid Valve Intervention
129        Resolving the Unmet Need for Treatment of Tricuspid Regurgitation
130        Bleeding after Transcatheter Structural Valve Interventions
 
HOT TOPICS  (Section - 16)          
PART 1: Heart Failure
131        Mitral Regurgitation in HF
132        Heart Failure and Aging
133        How does the Discontinuation of Long-Term Drug Treatment affectPatients With HFrEF
134        Metabolic defects in HFpEF and how to tackle them
135        Timing of Physical Activity and its impact on Cardiovascular Health
136        Impact of the EAT-Lancet Diet in Preventing Heart Failure
137        Cardiac Cachexia: Controversies and Conundrums
138        Therapeutic Inertia in the Treatment of HFrEF
139        ARNI-Induced Hypotension in HFrEF
140        The issue of Mortality Reduction in Patients With HFmrEF and HFpEF
141        HFrEF & HFpEF how they differ in advanced heart failure: A global perspective
142        Decongestion in acute heart failure: beyond diuretic-centred paradigm
143        Hepatic Biomarker Abnormalities in the Cardiac Intensive Care Unit Proposed Criteria for Cardiohepatic Syndrome
144        Bridging Atrial and Ventricular Failure Through Biomarkers
145        Ambulatory Advanced Heart Failure: Therapeutic Options
146        Interaction between Hypoalbuminemia and HF
147        Implications of Atrial Fibrillation for GDMT in Heart Failure
148        Challenges in Modifying Kidney Disease Progression in Patients With Heart Failure
 PART 2: Hypertension
149        Impact of Supranormal Left Ventricular Ejection Fraction, Concentric Remodeling in the Long-Term Survival
150        Brain Pathways in Regulating Blood Pressure
151        Update on Low-Renin Hypertension
152        Sodium, Interstitium, Lymphatics and Hypertension
153        Arterial Stiffness and Chronic Kidney Disease
PART 3: Coronary Artery Disease
154        Coronary Artery Spasm and Atherosclerotic Cardiovascular Disease
155        Peri-Infarct Ischemia and its Prognostic Significance
156        Hemorrhagic Myocardial Infarction
157        The issue of Stent Failure After PCI in patients with Diabetes Mellitus
158        Red blood cells as a new target for ASCVD prevention
159        Residual Chest Pain After PCI
 PART 4: Dislipidemia Management
160        HDL enhancing strategies and prevention of ASCVD
161        Cholesterol Screening and Management in Young Adults
 PART 5: Ischaemic Heart Disease
162        Vitamin D and Cardiovascular Risk
163        Testosterone and Cardiovascular Health
164        Primary Prevention for Intermediate CV Risk
165        Exposome in ischaemic heart disease
166        Interaction between Dietary Calcium and Vascular Calcification
167        Rethinking Beta Blocker in Stable Coronary Artery Disease
PART 6: Structural Intervention
168        PFO Closure for Stroke Prevention: An Illusion of Safety
PART 7: Heart & Brain
169        Role of Left Atrial Stiffness in the evaluation of Cryptogenic Stroke
PART 8: Cardiac Arrythmia
170        Appropriate use of defibrillator in non-ischaemic cardiomyopathy
171        Predicting Risk of Sudden Cardiac Death in Hypertrophic Cardiomyopathy: role of Radiomics
172        Anticoagulation for atrial fibrillation in patients with intermediate stroke risk
173        Digging up Digoxin: Should We Stop Prescribing it? Current views and perspectives
PART 9: Amyloidosis
174        Prognostic role of Amyloid burden
175        Predictors of outcome in AL Amyloidosis Patients With Cardiac Involvement
 
Top 10 Papers  (Section - 17)
176        Top 10 Papers in diabetes and metabolic disorders
177        Top 10 Papers in Anti-thrombotic
178        Top 10 papers in Lipids
179        Top 10 papers in Intervention
 
Viewpoint  (Section - 18)
PART 1: Obesity Paradox is a Fact
180        An Unexpected Relationship Between Body Weight and Health Outcomes (Proponent)
181        Myth or Reality (Opponent)
PART 2: Time Matters when Considering Treatment for Patients with Mitral Regurgitation
182        Time Matters When Considering Treatment for Patients with Mitral Regurgitation (Proponent)
183        Time Matters When Considering Treatment for Patients with Mitral Regurgitation (Opponent)
184        CHAD-VASC of 1 Not Same for Every Patient with Afib
185        How to Resolve the Prosthesis - Patient Mismatch Debate
186        AI will Replace Clinical Cardiology
 
Miscellaneous  (Section - 19)
187        Takayasu Arteritis - What is New?
188        Treatment of OSA & its impact on CVD
189        Participation in Sports by Athletes with CVD
190        Donor Selection for Heart Transplantation
191        Antithrombotic Therapies in Patients with Peripheral Artery Disease
192        Cardiology Training in India – Past Present and Future
193        Native Valve Infective Endocarditis: Recent Insights
194        Pulmonary Arterial Hypertension - no longer an orphan disease
195        Enigmas of the Athletic Heart
196        Cardiac Sarcoidosis: Diagnosis and Management
197        Marantic Endocarditis
198        Epilepsy and the heart: interaction between ‘brain arrhythmia’ and cardiac arrhythmia

Dhiman Kahali MD DM FESC FSCAI
Director, Interventional Cardiology, BM Birla Heart Research Centre, Kolkata, West Bengal, India; President Elect, Cardiological Society of India; Ex-Chairman, National Intervention Council, Cardiological Society of India (CSI); Ex-Convener, STEMI Council, Cardiological Society of India (CSI); Ex-Vice President,  Cardiological Society of India (CSI) 2020-2024
Debabrata Roy MD DM (Cardiology) FACC FESC FSCAI FAHA
Senior Consultant, Interventional Cardiologist and Academic Coordinator, NH-RTIICS, Kolkata, West Bengal, India